Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 18

1.

STAT3 antisense oligonucleotide AZD9150 in a subset of patients with heavily pretreated lymphoma: results of a phase 1b trial.

Reilley MJ, McCoon P, Cook C, Lyne P, Kurzrock R, Kim Y, Woessner R, Younes A, Nemunaitis J, Fowler N, Curran M, Liu Q, Zhou T, Schmidt J, Jo M, Lee SJ, Yamashita M, Hughes SG, Fayad L, Piha-Paul S, Nadella MVP, Xiao X, Hsu J, Revenko A, Monia BP, MacLeod AR, Hong DS.

J Immunother Cancer. 2018 Nov 16;6(1):119. doi: 10.1186/s40425-018-0436-5.

2.

AZD9150, a next-generation antisense oligonucleotide inhibitor of STAT3 with early evidence of clinical activity in lymphoma and lung cancer.

Hong D, Kurzrock R, Kim Y, Woessner R, Younes A, Nemunaitis J, Fowler N, Zhou T, Schmidt J, Jo M, Lee SJ, Yamashita M, Hughes SG, Fayad L, Piha-Paul S, Nadella MV, Mohseni M, Lawson D, Reimer C, Blakey DC, Xiao X, Hsu J, Revenko A, Monia BP, MacLeod AR.

Sci Transl Med. 2015 Nov 18;7(314):314ra185. doi: 10.1126/scitranslmed.aac5272.

3.

Renal biomarker changes associated with hyaline droplet nephropathy in rats are time and potentially compound dependent.

Brott DA, Bentley P, Nadella MV, Thurman D, Fikes J, Cheatham L, McGrath F, Luo W, Kinter LB.

Toxicology. 2013 Jan 7;303:133-8. doi: 10.1016/j.tox.2012.11.003. Epub 2012 Nov 14.

PMID:
23159986
4.

AU-rich elements in the 3'-UTR regulate the stability of the 141 amino acid isoform of parathyroid hormone-related protein mRNA.

Luchin AI, Nadella MV, Thudi NK, Dirksen WP, Gulati P, Fernandez SA, Rosol TJ.

Mol Cell Endocrinol. 2012 Nov 25;364(1-2):105-12. doi: 10.1016/j.mce.2012.08.015. Epub 2012 Aug 31.

5.

Comparisons of the efficacy of a Jak1/2 inhibitor (AZD1480) with a VEGF signaling inhibitor (cediranib) and sham treatments in mouse tumors using DCE-MRI, DW-MRI, and histology.

Loveless ME, Lawson D, Collins M, Nadella MV, Reimer C, Huszar D, Halliday J, Waterton JC, Gore JC, Yankeelov TE.

Neoplasia. 2012 Jan;14(1):54-64.

6.

Discovery of (+)-N-(3-aminopropyl)-N-[1-(5-benzyl-3-methyl-4-oxo-[1,2]thiazolo[5,4-d]pyrimidin-6-yl)-2-methylpropyl]-4-methylbenzamide (AZD4877), a kinesin spindle protein inhibitor and potential anticancer agent.

Theoclitou ME, Aquila B, Block MH, Brassil PJ, Castriotta L, Code E, Collins MP, Davies AM, Deegan T, Ezhuthachan J, Filla S, Freed E, Hu H, Huszar D, Jayaraman M, Lawson D, Lewis PM, Nadella MV, Oza V, Padmanilayam M, Pontz T, Ronco L, Russell D, Whitston D, Zheng X.

J Med Chem. 2011 Oct 13;54(19):6734-50. doi: 10.1021/jm200629m. Epub 2011 Sep 7.

PMID:
21899292
7.

Development of a brain metastatic canine prostate cancer cell line.

Thudi NK, Shu ST, Martin CK, Lanigan LG, Nadella MV, Van Bokhoven A, Werbeck JL, Simmons JK, Murahari S, Kisseberth WC, Breen M, Williams C, Chen CS, McCauley LK, Keller ET, Rosol TJ.

Prostate. 2011 Sep;71(12):1251-63. doi: 10.1002/pros.21341. Epub 2011 Feb 14.

8.

NOD/SCID mouse model of canine T-cell lymphoma with humoral hypercalcaemia of malignancy: cytokine gene expression profiling and in vivo bioluminescent imaging.

Nadella MV, Kisseberth WC, Nadella KS, Thudi NK, Thamm DH, McNiel EA, Yilmaz A, Boris-Lawrie K, Rosol TJ.

Vet Comp Oncol. 2008 Mar;6(1):39-54. doi: 10.1111/j.1476-5829.2007.00139.x.

9.

Expression of parathyroid hormone-related protein during immortalization of human peripheral blood mononuclear cells by HTLV-1: implications for transformation.

Nadella MV, Shu ST, Dirksen WP, Thudi NK, Nadella KS, Fernandez SA, Lairmore MD, Green PL, Rosol TJ.

Retrovirology. 2008 Jun 9;5:46. doi: 10.1186/1742-4690-5-46.

10.

Zoledronic acid decreased osteolysis but not bone metastasis in a nude mouse model of canine prostate cancer with mixed bone lesions.

Thudi NK, Martin CK, Nadella MV, Fernandez SA, Werbeck JL, Pinzone JJ, Rosol TJ.

Prostate. 2008 Jul 1;68(10):1116-25. doi: 10.1002/pros.20776.

11.

A novel bioluminescent mouse model and effective therapy for adult T-cell leukemia/lymphoma.

Shu ST, Nadella MV, Dirksen WP, Fernandez SA, Thudi NK, Werbeck JL, Lairmore MD, Rosol TJ.

Cancer Res. 2007 Dec 15;67(24):11859-66.

12.

Transcriptional regulation of parathyroid hormone-related protein promoter P2 by NF-kappaB in adult T-cell leukemia/lymphoma.

Nadella MV, Dirksen WP, Nadella KS, Shu S, Cheng AS, Morgenstern JA, Richard V, Fernandez SA, Huang TH, Guttridge D, Rosol TJ.

Leukemia. 2007 Aug;21(8):1752-62. Epub 2007 Jun 7.

13.

A novel canine lymphoma cell line: a translational and comparative model for lymphoma research.

Kisseberth WC, Nadella MV, Breen M, Thomas R, Duke SE, Murahari S, Kosarek CE, Vernau W, Avery AC, Burkhard MJ, Rosol TJ.

Leuk Res. 2007 Dec;31(12):1709-20. Epub 2007 May 29.

PMID:
17532464
14.

Parathyroid hormone-related protein and ezrin are up-regulated in human lung cancer bone metastases.

Deng X, Tannehill-Gregg SH, Nadella MV, He G, Levine A, Cao Y, Rosol TJ.

Clin Exp Metastasis. 2007;24(2):107-19. Epub 2007 Mar 17.

PMID:
17370040
15.

The effect of zoledronic acid and osteoprotegerin on growth of human lung cancer in the tibias of nude mice.

Tannehill-Gregg SH, Levine AL, Nadella MV, Iguchi H, Rosol TJ.

Clin Exp Metastasis. 2006;23(1):19-31. Epub 2006 May 20.

PMID:
16715352
16.

New bone formation and osteolysis by a metastatic, highly invasive canine prostate carcinoma xenograft.

LeRoy BE, Thudi NK, Nadella MV, Toribio RE, Tannehill-Gregg SH, van Bokhoven A, Davis D, Corn S, Rosol TJ.

Prostate. 2006 Aug 1;66(11):1213-22.

PMID:
16683269
17.

Transcriptional regulation of parathyroid hormone-related protein promoter P3 by ETS-1 in adult T-cell leukemia/lymphoma.

Richard V, Nadella MV, Green PL, Lairmore MD, Feuer G, Foley JG, Rosol TJ.

Leukemia. 2005 Jul;19(7):1175-83.

18.

Canine prostate carcinomas express markers of urothelial and prostatic differentiation.

LeRoy BE, Nadella MV, Toribio RE, Leav I, Rosol TJ.

Vet Pathol. 2004 Mar;41(2):131-40.

PMID:
15017026

Supplemental Content

Loading ...
Support Center